Taysha Gene Therapies (TSHA) Total Liabilities (2019 - 2026)
Taysha Gene Therapies (TSHA) posted Total Liabilities of $88.4 million for Q1 2026, down 8.27% sequentially from $96.4 million in Q4 2025, and up 6.13% YoY from $83.3 million in Q1 2025.
Taysha Gene Therapies (TSHA) Total Liabilities (2019 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Total Liabilities for 8 years, with the latest figure at $88.4 million in Q1 2026.
- Quarterly Total Liabilities rose 6.13% year-over-year to $88.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.4 million (up 6.13% YoY) and the FY2025 annual result came in at $96.4 million, up 8.49% from the prior year.
- Total Liabilities slipped to $88.4 million in Q1 2026 per TSHA's latest filing, from $96.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $244.9 million in Q3 2023 and troughed at $83.3 million in Q1 2025.
- A 5-year average of $108.8 million and a median of $97.8 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities jumped 477.5% in 2022, then slumped 62.67% in 2024.
- Over 5 years, Total Liabilities stood at $125.3 million in 2022, then declined by 21.97% to $97.8 million in 2023, then declined by 9.16% to $88.8 million in 2024, then grew by 8.49% to $96.4 million in 2025, then declined by 8.27% to $88.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $88.4 million, $96.4 million, and $97.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 83.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.17 Mn |
| Mar 31, 2026 | 88.41 Mn |
| Dec 31, 2025 | 96.38 Mn |
| Sep 30, 2025 | 97.57 Mn |
| Jun 30, 2025 | 84.60 Mn |
| Mar 31, 2025 | 83.30 Mn |
| Dec 31, 2024 | 88.84 Mn |
| Sep 30, 2024 | 91.42 Mn |
| Jun 30, 2024 | 91.53 Mn |
| Mar 31, 2024 | 99.15 Mn |
| Dec 31, 2023 | 97.79 Mn |
| Sep 30, 2023 | 244.88 Mn |
| Jun 30, 2023 | 118.66 Mn |
| Mar 31, 2023 | 116.55 Mn |
| Dec 31, 2022 | 125.33 Mn |
| Sep 30, 2022 | 100.34 Mn |
| Jun 30, 2022 | 109.62 Mn |
| Mar 31, 2022 | 115.25 Mn |
| Dec 31, 2021 | 118.57 Mn |
| Sep 30, 2021 | 100.65 Mn |